Daily Low-Dose Ketamine: Does It Work for Depression?

What Is Low-Dose Ketamine Therapy?

Low-dose ketamine therapy involves using sub-anesthetic amounts of the medication prescribed by a licensed provider to treat mental health conditions. Ketamine has been an FDA-approved anesthetic since 1970 and has been on the WHO List of Essential Medicines since 1985.³ Prescribing it for depression is off-label, which is a widespread and legally accepted practice in psychiatry.⁴

What Is the Difference Between Microdose, Low-Dose, and Therapeutic-Dose Ketamine?

In commercial use, "microdose," "low-dose," and "sub-perceptual" often refer to the same thing: a dose small enough that the patient experiences little to no dissociation or perceptual changes during administration. In practice, these protocols are taken at home as part of a daily routine, similar to other prescribed medications. There is no structured treatment session built around the dose; the patient takes it and continues their day.

Therapeutic-dose ketamine is a different category. Therapeutic doses are large enough to produce perceptual changes (dissociation, altered perception of time and self), and those perceptual changes are considered part of the treatment mechanism. Therapeutic doses are individually titrated by a licensed provider based on patient response, treatment history, and clinical assessment, not fixed across patients. Treatments are structured around dedicated sessions on a periodic schedule, typically with preparation beforehand, the dosing experience within a defined treatment window, and a settling period afterward before returning to normal activities.

The distinction matters for evaluating research: studies using sub-perceptual doses on daily schedules are testing a fundamentally different intervention than studies using therapeutic doses on periodic schedules. Findings from one category do not generalize to the other.

• Sub-perceptual or microdose ketamine: typically around 10-30 mg, often intended to minimize dissociative or perceptual effects, used in commercial daily protocols.
• Therapeutic-dose ketamine: individually titrated by a clinician, perceptual changes expected as part of the mechanism, used in periodic dosing protocols.

What Is the Difference Between Esketamine and Ketamine?

Racemic ketamine is a 50:50 mixture of S-enantiomers and R-enantiomers. Esketamine is the S-enantiomer alone, possessing approximately three to four times higher NMDA receptor affinity than R-ketamine.

The only FDA-approved ketamine product for depression is intranasal esketamine (Spravato). The FDA approved it for treatment-resistant depression and, subsequently, for depressive symptoms in adults with major depressive disorder with acute suicidal ideation or behavior, requiring administration under REMS guidelines in certified healthcare settings.⁵

Most commercial at-home ketamine therapy providers prescribe racemic ketamine rather than esketamine.

What Does the Research Say About Daily Low-Dose Ketamine?

No published clinical trial has ever tested daily oral racemic ketamine for depression in the general outpatient population commercial daily-dosing providers serve. Three studies come close, but each diverges from the commercial protocol on at least one critical dimension.

The closest proxy by drug and schedule is a 14-patient open-label proof-of-concept that matched the once-daily schedule and the racemic compound, but enrolled hospice patients with advanced or terminal illness, not general outpatients (Irwin 2013).¹⁰ Six of the 14 enrolled patients did not complete the 28-day trial, and the authors themselves called for randomized controlled trials before efficacy could be considered established. It is the closest match on what was studied, but it diverges on the population it was studied in.

The other two studies diverge on different dimensions. One used the more potent esketamine compound, dosed three times daily rather than once.¹ The other used the same oral racemic ketamine compound but on a thrice-weekly schedule rather than daily.⁶ The full protocols are below.

Study 1: Irwin 2013¹⁰

• Drug: Oral racemic ketamine
• Schedule: Once daily for 28 days
• Dose: 0.5 mg/kg
• Sample: n=14 enrolled, 8 completed (43% dropout)
• Population: Hospice patients with advanced or terminal illness
• Results: 100% response in completers (8/8) on the Hospital Anxiety and Depression Scale; intent-to-treat response 57% (8 of 14 enrolled). Cohen's d at day 28: 1.34.
• Side effects: Rare; most common were diarrhea, trouble sleeping, and trouble sitting still. No serious adverse events.
• Authors' note: Randomized controlled trials are needed to firmly establish efficacy.

Study 2: Smith-Apeldoorn 2022¹

• Drug: Oral esketamine (not racemic ketamine)
• Schedule: Three times daily for 21 days
• Total daily dose: Titrated to 1.25 mg/kg
• Sample: n=7
• Results: 0/7 response, 0/7 remission, 16.5% HRSD reduction
• Authors' conclusion: "Therapeutic effects were modest"

Study 3: Domany 2019⁶

• Drug: Oral racemic ketamine (matches commercial drug)
• Schedule: Thrice-weekly for 21 days (not daily)
• Dose: 1 mg/kg
• Sample: RCT, n=41
• Results: 31.8% response, 27.3% remission

No other prospective clinical trial has tested an oral ketamine protocol at this dose range and frequency. The team behind the Smith-Apeldoorn pilot did publish a larger follow-up several years later — with a different schedule.²

What Did Follow-Up Research on Oral Ketamine Find?

When the same research group behind the 2022 daily esketamine trial scaled up to 185 patients in 2025, they did not replicate the daily schedule. They used the same drug — oral esketamine — but moved from three-times-daily dosing in their 7-patient pilot to twice-weekly dosing in the larger study.²

The follow-up enrolled participants with severe treatment-resistant depression, averaging 8.1 prior antidepressant failures, with 63% ECT-resistant. Response reached 26.8%, remission 15.6%, and HDRS scores declined by 25.5%.

What Does This Research Suggest About Daily Low-Dose Ketamine Effectiveness?

The published evidence cannot fully answer the question. The studies that exist are all small, each diverges from the commercial protocol on more than one dimension, and their results do not converge on a clear picture: favorable response in 8 hospice completers,¹⁰ no response in 7 severe-TRD patients on a more intensive schedule,¹ and a follow-up team that moved off daily dosing when they scaled up.²

Whether daily oral racemic ketamine is effective for depression in the general outpatient population commercial providers serve has not been addressed in published prospective research.

How Does Other Ketamine Research Compare?

By contrast, the published evidence on periodic-dosing schedules is dramatically larger — both in number of patients studied and in methodological rigor. With one exception, every prospective oral or sublingual ketamine trial that has reported response or remission for depression used a periodic schedule, ranging from thrice-weekly to roughly weekly.

Sample sizes in this literature range from a 41-patient placebo-controlled RCT to a real-world effectiveness study of more than 11,000 patients. Response rates range from 26.8% to 56.4%. Three of these studies are summarized below; direct comparisons across studies should account for differences in study design, patient populations, and outcome measures.

The Mathai 2024 data represents a real-world effectiveness study of Mindbloom's at-home sublingual ketamine therapy program.⁷

What Is Known About the Safety of Daily or Frequent Ketamine Protocols?

Very little is known about the safety of the daily low-dose protocol commercial providers prescribe to general outpatients. The published safety data for ketamine in depression comes almost entirely from periodic therapeutic-dose protocols, which have been studied across thousands of patients in multiple peer-reviewed trials. That data does not extrapolate cleanly to daily sub-perceptual protocols, which use different dose ranges, different administration patterns, and a different patient experience.

Put plainly: in the general outpatient population commercial providers serve, and over the months or years of continuous use these providers market, this protocol has not been shown to be safe in any published prospective research. It also has not been shown to be unsafe. The peer-reviewed literature does not answer the question in either direction.

What Are Common Short-Term Side Effects?

For the commercial daily low-dose protocol in the general outpatient population, the side effect profile has not been characterized. The only window into daily oral racemic ketamine in depression comes from 8 hospice patients, where side effects were rare; the most common were diarrhea, trouble sleeping, and trouble sitting still, with no serious adverse events.¹⁰

A separate trial of three-times-daily oral esketamine — a different, more potent compound — in 7 patients with severe treatment-resistant depression for 21 days reported psychotomimetic effects as the most common side effects, with no serious adverse events.¹ Another 2013 study reported no psychotomimetic or dissociative effects at a very low 10 mg sublingual dose used on a periodic (not daily) schedule.⁸

In other words, the side effect profile of a daily, low-dose ketamine protocol in the general outpatient population is not currently known.

What Does the Published Evidence Show About Long-Term Daily Ketamine Use?

Very little is known about the safety of long-term, low-dose daily ketamine treatment. The longest prospective trial of any daily oral ketamine protocol for depression lasted 28 days.¹⁰ No peer-reviewed prospective study has measured outcomes at 3 months, 6 months, 1 year, or longer.

Commercial daily-dosing protocols are marketed for ongoing or indefinite use — months or years of continuous daily dosing. No published prospective study has examined that range. Long-term use of this protocol has not been shown to be safe in published prospective research. It also has not been shown to be unsafe. The peer-reviewed literature does not address the question in either direction.

Who Should Not Use Ketamine Therapy?

Eligibility is a medical assessment process, not a set of binary rules. Not everyone is a good candidate for ketamine therapy — it may not be appropriate for individuals with uncontrolled hypertension, active psychotic disorders, active substance use disorders, pregnancy, and certain cardiac or respiratory conditions.

A licensed provider evaluates these factors during the screening process described above. Comprehensive medical screening before treatment is a core component of responsible ketamine therapy, not an optional step.

• Uncontrolled hypertension: Ketamine's sympathomimetic properties make cardiovascular screening essential.
• Active psychotic disorders: Ketamine's perceptual effects may not be appropriate.
• Active substance use disorders: Requires medical evaluation given ketamine's Schedule III classification.
• Pregnancy: Insufficient data on use during pregnancy.
• Certain cardiac or respiratory conditions: A specialist evaluates on a case-by-case basis.

Is Low-Dose Ketamine Addictive?

The single published prospective trial of daily oral racemic ketamine for depression did not characterize abuse, dependence, or tolerance, but was likely too short and too small to detect any of these outcomes if they did occur.¹⁰ In the broader published literature on supervised, sub-anesthetic ketamine use, abuse and dependence risk has generally been characterized as low.

Ketamine is classified as a Schedule III controlled substance by the DEA, indicating accepted medical use and a potential for abuse that may lead to moderate or low physical dependence or high psychological dependence. Documented dependence and tolerance are primarily from recreational contexts involving higher doses and unsupervised use.⁹

Whether the specific daily low-dose protocol carries distinct abuse or dependence risks has not been studied in peer-reviewed research. The protocol has not been shown to be non-addictive, and it has not been shown to be addictive. The question is unresolved in the peer-reviewed literature.

Conclusion

The published research on daily low-dose oral ketamine for depression has two defining features: it is small in scale, and it has not tested the protocol in the patient population the protocol is marketed to. Across both prospective trials of daily oral dosing combined, 21 patients were enrolled and 15 completed. The longer of the two trials lasted 28 days.

Neither trial directly tested what commercial daily-dosing providers prescribe. Irwin 2013 matched the drug and once-daily schedule but enrolled hospice patients with advanced or terminal illness, not general outpatients. Smith-Apeldoorn 2022 enrolled non-hospice patients but used a different drug — esketamine, not racemic ketamine — on a more intensive three-times-daily schedule.

By contrast, the published evidence on periodic-dosing protocols includes a placebo-controlled randomized controlled trial, multiple open-label trials, and a real-world effectiveness study of more than 11,000 patients, with response rates between 26.8% and 56.4%.

Everything beyond one month of daily low-dose use is currently unanswered in the published literature — long-term effectiveness, long-term safety, side effects with sustained use, tolerance, dependence. However, commercial providers market these protocols for months or years of continuous use.

Important Safety Information

Ketamine is not FDA-approved for PTSD, depression, or anxiety. Common side effects include dissociation, increased blood pressure, nausea, dizziness, and cognitive impairment. Ketamine has abuse potential and may not be appropriate for patients with uncontrolled hypertension, active psychotic disorders, or certain substance use disorders; a licensed clinician should assess individual risk before treatment. Do not drive or operate machinery until the day after treatment. Individual results may vary. Full safety information: www.mindbloom.com/safety-information

Off-Label Use Disclosure

Ketamine is FDA-approved only as an anesthetic. Use for mental health conditions represents off-label prescribing by licensed clinicians based on clinical judgment. Schedule III Controlled Substance - DEA regulations apply.